Literature DB >> 17828584

Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.

Alberto Mantovani1, Cecilia Garlanda, Andrea Doni, Barbara Bottazzi.   

Abstract

Pentraxins are a family of multimeric pattern-recognition proteins highly conserved in evolution. Based on the primary structure of the subunit, the pentraxins are divided into two groups: short pentraxins and long pentraxins. C-reactive protein and serum amyloid P-component are classic short pentraxins produced in the liver, whereas the prototype of the long pentraxin family is PTX3. Innate immunity cells and vascular cells produce PTX3 in response to proinflammatory signals and Toll-like receptor engagement. PTX3 interacts with several ligands, including growth factors, extracellular matrix components, and selected pathogens, playing a role in complement activation, facilitating pathogen recognition, and acting as a predecessor of antibodies. In addition, PTX3 is essential in female fertility acting on the assembly of the cumulus oophorus extracellular matrix. Thus, PTX3 is a multifunctional soluble pattern recognition receptor acting as a nonredundant component of the humoral arm of innate immunity and involved in tuning inflammation, in matrix deposition and female fertility. Evidence suggests that PTX3 is a useful new serological marker, rapidly reflecting tissue inflammation and damage under diverse clinical conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828584     DOI: 10.1007/s10875-007-9126-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  99 in total

1.  PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans.

Authors:  G Peri; M Introna; D Corradi; G Iacuitti; S Signorini; F Avanzini; F Pizzetti; A P Maggioni; T Moccetti; M Metra; L D Cas; P Ghezzi; J D Sipe; G Re; G Olivetti; A Mantovani; R Latini
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

2.  Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.

Authors:  D Agnello; L Carvelli; V Muzio; P Villa; B Bottazzi; N Polentarutti; T Mennini; A Mantovani; P Ghezzi
Journal:  J Neuroimmunol       Date:  2000-09-22       Impact factor: 3.478

3.  Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia.

Authors:  B K Rinehart; D A Terrone; S Lagoo-Deenadayalan; W H Barber; E A Hale; J N Martin; W A Bennett
Journal:  Am J Obstet Gynecol       Date:  1999-10       Impact factor: 8.661

4.  Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation.

Authors:  Silvia Bozza; Francesco Bistoni; Roberta Gaziano; Lucia Pitzurra; Teresa Zelante; Pierluigi Bonifazi; Katia Perruccio; Silvia Bellocchio; Mariella Neri; Anna Maria Iorio; Giovanni Salvatori; Rita De Santis; Mario Calvitti; Andrea Doni; Cecilia Garlanda; Alberto Mantovani; Luigina Romani
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

5.  Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells.

Authors:  Andrea Doni; Giuseppe Peri; Marcello Chieppa; Paola Allavena; Fabio Pasqualini; Luca Vago; Luigina Romani; Cecilia Garlanda; Alberto Mantovani
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

6.  PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages.

Authors:  S N Diniz; R Nomizo; P S Cisalpino; M M Teixeira; G D Brown; A Mantovani; S Gordon; L F L Reis; A A M Dias
Journal:  J Leukoc Biol       Date:  2004-01-14       Impact factor: 4.962

7.  The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation.

Authors:  Emanuela Napoleone; Angelomaria di Santo; Giuseppe Peri; Alberto Mantovani; Giovanni de Gaetano; Maria Benedetta Donati; Roberto Lorenzet
Journal:  J Leukoc Biol       Date:  2004-07       Impact factor: 4.962

8.  Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality.

Authors:  Mengli Tong; Juan Jesús Carrero; A Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Anders Alvestrand; Peter Stenvinkel; Bengt Lindholm; Mohamed E Suliman
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

9.  The sperm acrosomal matrix contains a novel member of the pentaxin family of calcium-dependent binding proteins.

Authors:  T D Noland; B B Friday; M T Maulit; G L Gerton
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

10.  Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.

Authors:  Marco Rusnati; Maura Camozzi; Emanuela Moroni; Barbara Bottazzi; Giuseppe Peri; Stefano Indraccolo; Alberto Amadori; Alberto Mantovani; Marco Presta
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

View more
  142 in total

1.  Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study.

Authors:  A R Pradeep; Rahul Kathariya; P Arjun Raju; R Sushma Rani; Anuj Sharma; N M Raghavendra
Journal:  Int Urol Nephrol       Date:  2011-06-03       Impact factor: 2.370

2.  Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury.

Authors:  Bing Han; Jack J Haitsma; Yu Zhang; Xiaohui Bai; Matthew Rubacha; Shaf Keshavjee; Haibo Zhang; Mingyao Liu
Journal:  Intensive Care Med       Date:  2010-11-12       Impact factor: 17.440

3.  Pentraxin3 and high-sensitive C-reactive protein are independent inflammatory markers released during high-intensity exercise.

Authors:  Toshiaki Nakajima; Miwa Kurano; Takaaki Hasegawa; Haruhito Takano; Haruko Iida; Tomohiro Yasuda; Taira Fukuda; Haruhiko Madarame; Kansei Uno; Kentaro Meguro; Taro Shiga; Mina Sagara; Taiji Nagata; Koji Maemura; Yasunobu Hirata; Tatsuya Yamasoba; Ryozo Nagai
Journal:  Eur J Appl Physiol       Date:  2010-07-17       Impact factor: 3.078

Review 4.  Acute Phase Proteins and Their Role in Periodontitis: A Review.

Authors:  Tejaswin Polepalle; Srinivas Moogala; Shalini Boggarapu; Divya Sai Pesala; Firoz Babu Palagi
Journal:  J Clin Diagn Res       Date:  2015-11-01

5.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

6.  The Long Pentraxin 3 Contributes to Joint Inflammation in Gout by Facilitating the Phagocytosis of Monosodium Urate Crystals.

Authors:  Nathália V Batista; Marialuisa Barbagallo; Vivian L S Oliveira; Thiago Castro-Gomes; Rene D R Oliveira; Paulo Louzada-Junior; Geraldo R C Pinheiro; Alberto Mantovani; Mauro M Teixeira; Cecilia Garlanda; Flávio A Amaral
Journal:  J Immunol       Date:  2019-02-04       Impact factor: 5.422

7.  The genomic determinants of alcohol preference in mice.

Authors:  Boris Tabakoff; Laura Saba; Katherina Kechris; Wei Hu; Sanjiv V Bhave; Deborah A Finn; Nicholas J Grahame; Paula L Hoffman
Journal:  Mamm Genome       Date:  2008-06-19       Impact factor: 2.957

8.  Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.

Authors:  Hao Wang; Stephen J Atkins; Roshini Fernando; Rui-Li Wei; Terry J Smith
Journal:  Endocrinology       Date:  2015-08-19       Impact factor: 4.736

9.  The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice.

Authors:  Danielle G Souza; Flavio A Amaral; Caio T Fagundes; Fernanda M Coelho; Rosa M E Arantes; Lirlandia P Sousa; Martin M Matzuk; Cecília Garlanda; Alberto Mantovani; Adriana A Dias; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

10.  Regulation of pentraxin-3 by antioxidants.

Authors:  A L Hill; D A Lowes; N R Webster; C C Sheth; N A R Gow; H F Galley
Journal:  Br J Anaesth       Date:  2009-10-28       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.